# QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

> **NCT00626106** · PHASE2 · COMPLETED · sponsor: **NantCell, Inc.** · enrollment: 156 (actual)

## Conditions studied

- Breast Cancer
- Breast Tumors
- Metastatic Cancer

## Interventions

- **DRUG:** AMG 479
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00626106
- **Lead sponsor:** NantCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-27
- **Primary completion:** 2010-05-05
- **Final completion:** 2011-09-23
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626106, "QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00626106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*